DOCSLIB.ORG

Protection of the Human Gut Microbiome From

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protection of the Human Gut Microbiome From Protection of the Human Gut Microbiome From Antibiotics Jean de Gunzburg, Amine Ghozlane, Annie Ducher, Emmanuelle Le Chatelier, Xavier Duval, Etienne Ruppé, Laurence Armand-Lefevre, Frédérique Sablier-Gallis, Charles Burdet, Loubna Alavoine, et al. To cite this version: Jean de Gunzburg, Amine Ghozlane, Annie Ducher, Emmanuelle Le Chatelier, Xavier Duval, et al.. Protection of the Human Gut Microbiome From Antibiotics. Journal of Infectious Diseases, Oxford University Press (OUP), 2018, 217 (4), pp.628-636. 10.1093/infdis/jix604. pasteur-02552147 HAL Id: pasteur-02552147 https://hal-pasteur.archives-ouvertes.fr/pasteur-02552147 Submitted on 23 Apr 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License The Journal of Infectious Diseases MAJOR ARTICLE Protection of the Human Gut Microbiome From Antibiotics Jean de Gunzburg,1,a Amine Ghozlane,2,a Annie Ducher,1,a Emmanuelle Le Chatelier,2,a Xavier Duval,3,4,5 Etienne Ruppé,2,b Laurence Armand-Lefevre,3,4,5 Frédérique Sablier-Gallis,1 Charles Burdet,4,5 Loubna Alavoine,3 Elisabeth Chachaty,6 Violaine Augustin,1 Marina Varastet,1 Florence Levenez,2 Sean Kennedy,2,b Nicolas Pons,2 France Mentré,4,5,c and Antoine Andremont3,4,5,c 1Da Volterra, Paris; 2Metagenopolis, Institut National de la Recherche Agronomique, Jouy-en-Josas; 3Bichat Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris 217 Cité, 4Institut National de la Santé et de la Recherche Médicale, Infection Antimicrobials Modelling Evolution, Unité Mixte de Recherche 1137, and 5University Paris Diderot, Sorbonne Paris Cité, Paris; and 5Institut Gustave-Roussy, Villejuif, France Downloaded from https://academic.oup.com/jid/article-abstract/217/4/628/4653556 by Institut Pasteur user on 23 April 2020 15 Background. Antibiotics are life-saving drugs but severely affect the gut microbiome with short-term consequences including diarrhea and selection of antibiotic-resistant bacteria. Long-term links to allergy and obesity are also suggested. We devised a product, February DAV132, and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the late ileum of human volunteers. Methods. We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving DAV132 alone, or a nonactive substitute, were added. Results. The coadministration of DAV132 decreased free moxifloxacin fecal concentrations by 99%, while plasmatic levels were unaffected. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects co-treated with DAV132 in addition to moxifloxacin. No adverse effect was observed. In addition, DAV132 efficiently adsorbed a wide range of clinically relevant antibiotics ex vivo. Conclusions. DAV132 was highly effective to protect the gut microbiome of moxifloxacin-treated healthy volunteers and may constitute a clinical breakthrough by preventing adverse health consequences of a wide range of antibiotic treatments. Clinical Trials Registration. NCT02176005. Keywords. microbiome; antibiotics; fluoroquinolones; Clostridium difficile. Antibiotics constitute one of the most medically important and community patients [9–11]. Long-term links to allergy [4] and effective class of drugs. However, during systemic antibiotic treat- obesity [5] have also been suggested. Indeed, burgeoning research ments, the nonabsorbed part of orally administered drugs, as well in recent years has shown that the intestinal microbiome plays an as the possible fraction excreted into the upper intestine via bile important role in many aspects of human physiology and health for both oral and parenteral antibiotics, reaches the cecum and [12]. In particular, it is involved in the production of metabolites STANDARD colon where it can exert devastating effects on the gut microbi- that may affect insulin sensitivity [13] and diet-related obesity ome, with short- and long-term consequences [1–5]. Short-term [14]; this state has been shown to correlate with a gut microbi- effects include diarrhea, Clostridium difficile infection (CDI), and ome of lower bacterial richness than in healthy individuals [15]. selection of antibiotic-resistant microorganisms [6–8]. CDI cur- Strategies that would preserve the intestinal microbiome from rently constitutes a major clinical challenge, and antibiotic treat- deleterious consequences of dysbiosis during antibiotic treat- ments are the key factor for their occurrence in hospitalized and ments would be highly welcome for immediate protection of patients from CDI, and also for long-term public health conse- quences such as dissemination of resistant bacteria and the occur- Received 30 July 2017; editorial decision 15 November 2017; accepted 19 November 2017; rence of metabolic disorders. Oral administration of a β-lactamase published online November 23, 2017. [16–20] prevented the impact of parenteral β-lactams on the Presented in part: IDWeek, San Diego, California, October 2015 (abstract 760). aJ. G., A. G., and A. D. contributed equally to this work. microbiome, which is promising but limited to this class of anti- bPresent affiliation: E.R., INSERM, IAME, UMR 1137, Paris, France; University Paris Diderot, biotics. Delivering a nonspecific adsorbent to the colon partially Sorbonne Paris Cité, 75018 Paris, France; A.G. and S.K., Institut Pasteur, 75015 Paris, France. cF. M. and A. A. contributed equally to this work. decreased fecal concentrations of orally administered ciprofloxa- Correspondence: J. de Gunzburg, PhD, Da Volterra, 75011 Paris, France (gunzburg@davolterra. cin without significantly affecting its plasma pharmacokinetics in com). The Journal of Infectious Diseases® 2018;217:628–36 rats [21]. We devised a product, DAV132, which delivers a pow- © The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases erful nonspecific adsorbent, a carefully chosen activated charcoal, Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ to the late ileum in humans, and have shown in healthy volunteers by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any that its administration did not affect the plasma pharmacokinetics medium, provided the original work is not altered or transformed in any way, and that the of amoxicillin, given as a single dose [22]. Here, we performed a work is properly cited. For commercial re-use, please contact [email protected] DOI: 10.1093/infdis/jix604 randomized clinical trial in volunteers receiving a full oral clinical 628 • JID 2018:217 (15 February) • de Gunzburg et al course of the fluoroquinolone antibiotic moxifloxacin (MXF), and evaluations, at the Clinical Investigation Centre of the Bichat assessed DAV132 safety, as well as its resulting effects on MXF Hospital, Paris (France) in respect with Good Clinical plasma concentrations, MXF free fecal concentrations, and intes- Practice and the Declaration of Helsinki as last amended. tinal dysbiosis. We also evaluated ex vivo the capacity of DAV132 Volunteers were randomized (Supplementary Materials) to adsorb a wide range of clinically relevant antibiotics. to receive either MXF alone (n = 14), MXF + DAV132 (n = 14), DAV132 alone (n = 8), or CTL (n = 8) (Figure 1). METHODS The study was carried out after authorizations from French Investigational Products Health Authorities and the Independent Ethics Committee DAV132 was manufactured according to Da Volterra’s specifi- (“Comité de Protection des Personnes Ile-de-France IV,” cations [22] under Good Manufacturing Practice conditions at Paris, France) had been obtained (January and February NextPharma (Bielefeld, Germany). The dosage form, consisting 2014, respectively). It was declared in ClinicalTrials.gov of 7.5 g DAV132, contained 5.11 g activated charcoal as active (identifier NCT02176005) and the French (ID-RCB number Downloaded from https://academic.oup.com/jid/article-abstract/217/4/628/4653556 by Institut Pasteur user on 23 April 2020 adsorbing ingredient. To facilitate oral intake, DAV132 pellets 2013-A01504-41) registers of clinical trials. A study-specific were suspended in an extemporaneously prepared gel suspen- scientific committee (A. A., V. A., A. Duc., A. Duf., X. D., C. F., sion (batch number C1311007). A negative control (CTL) was J. G., F. M., and M. V.) was set up to ensure scientific integrity. made of a product similar to DAV132, in which the adsorb- ent was replaced by microcrystalline cellulose (batch number Treatments C1311006). MXF was from Bayer (Avalox 400 mg Filmtabletten, Moxifloxacin 400 mg was administered orally, once a day (after batch number BXGFBN1). breakfast)
Load more

Recommended publications
  • Shotgun Metagenomics of 361 Elderly Women Reveals Gut Microbiome
    bioRxiv preprint doi: https://doi.org/10.1101/679985; this version posted June 23, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Shotgun Metagenomics of 361 elderly women reveals gut microbiome change in bone mass loss Qi Wang1,2,3,4, *, Hui Zhao1,2,3,4, *, Qiang Sun2,5, *, Xiaoping Li3,4, *, Juanjuan Chen3,4, Zhefeng Wang6, Yanmei Ju2,3,4, Zhuye Jie3,4, Ruijin Guo3,4,7,8, Yuhu Liang2, Xiaohuan Sun3,4, Haotian Zheng3,4, Tao Zhang3,4, Liang Xiao3,4, Xun Xu3,4, Huanming Yang3,9, Songlin Peng6, †, Huijue Jia3,4,7,8, †. 1. School of Future Technology, University of Chinese Academy of Sciences, Beijing, 101408, China. 2. BGI Education Center, University of Chinese Academy of Sciences, Shenzhen 518083, China; 3. BGI-Shenzhen, Shenzhen 518083, China; 4. China National Genebank, Shenzhen 518120, China; 5. Department of Statistical Sciences, University of Toronto, Toronto, Canada; 6. Department of Spine Surgery, Shenzhen People's Hospital, Ji Nan University Second College of Medicine, 518020, Shenzhen, China. 7. Macau University of Science and Technology, Taipa, Macau 999078, China; 8. Shenzhen Key Laboratory of Human Commensal Microorganisms and Health Research, BGI-Shenzhen, Shenzhen 518083, China; 9. James D. Watson Institute of Genome Sciences, 310058 Hangzhou, China; * These authors have contributed equally to this study †Corresponding authors: S.P., [email protected]; H.J., [email protected]; bioRxiv preprint doi: https://doi.org/10.1101/679985; this version posted June 23, 2019.
    [Show full text]
  • WO 2018/064165 A2 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder
    International Journal of Molecular Sciences Review The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder Piranavie Srikantha and M. Hasan Mohajeri * Department of medicine, University of Zurich, Winterthurerstrasse 190, 8057 Zürich, Switzerland; [email protected] * Correspondence: [email protected]; Tel.: +41-79-938-1203 Received: 27 March 2019; Accepted: 28 April 2019; Published: 29 April 2019 Abstract: New research points to a possible link between autism spectrum disorder (ASD) and the gut microbiota as many autistic children have co-occurring gastrointestinal problems. This review focuses on specific alterations of gut microbiota mostly observed in autistic patients. Particularly, the mechanisms through which such alterations may trigger the production of the bacterial metabolites, or leaky gut in autistic people are described. Various altered metabolite levels were observed in the blood and urine of autistic children, many of which were of bacterial origin such as short chain fatty acids (SCFAs), indoles and lipopolysaccharides (LPS). A less integrative gut-blood-barrier is abundant in autistic individuals. This explains the leakage of bacterial metabolites into the patients, triggering new body responses or an altered metabolism. Some other co-occurring symptoms such as mitochondrial dysfunction, oxidative stress in cells, altered tight junctions in the blood-brain barrier and structural changes in the cortex, hippocampus, amygdala and cerebellum were also detected. Moreover, this paper suggests that ASD is associated with an unbalanced gut microbiota (dysbiosis). Although the cause-effect relationship between ASD and gut microbiota is not yet well established, the consumption of specific probiotics may represent a side-effect free tool to re-establish gut homeostasis and promote gut health.
    [Show full text]
  • Mucosal Prevalence and Interactions with the Epithelium Indicate Commensalism of Sutterella Spp
    fmicb-07-01706 October 24, 2016 Time: 15:3 # 1 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto ORIGINAL RESEARCH published: 26 October 2016 doi: 10.3389/fmicb.2016.01706 Mucosal Prevalence and Interactions with the Epithelium Indicate Commensalism of Sutterella spp. Kaisa Hiippala1*, Veera Kainulainen2, Marko Kalliomäki3, Perttu Arkkila4 and Reetta Satokari1 1 Immunobiology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland, 2 Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland, 3 Department of Pediatrics, Turku University Central Hospital and Functional Foods Forum, University of Turku, Turku, Finland, 4 Department of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland Sutterella species have been frequently associated with human diseases, such as autism, Down syndrome, and inflammatory bowel disease (IBD), but the impact of these bacteria on health still remains unclear. Especially the interactions of Sutterella spp. with the host are largely unknown, despite of the species being highly prevalent. Edited by: M. P. Francino, In this study, we addressed the interaction of three known species of Sutterella with FISABIO-Generalitat Valenciana, the intestinal epithelium and examined their adhesion properties, the effect on intestinal Spain barrier function and the pro-inflammatory capacity in vitro. We also studied the relative Reviewed by: abundance and prevalence of the genus Sutterella and Sutterella wadsworthensis Christian U. Riedel, University of Ulm, Germany in intestinal biopsies of healthy individuals and patients with celiac disease (CeD) or Suzanne L. Ishaq, IBD. Our results show that Sutterella spp. are abundant in the duodenum of healthy Montana State University, USA adults with a decreasing gradient toward the colon.
    [Show full text]
  • The Role of the Intestinal Microbiota in Inflammatory Bowel Disease Seth Bloom Washington University in St
    Washington University in St. Louis Washington University Open Scholarship All Theses and Dissertations (ETDs) 1-1-2012 The Role of the Intestinal Microbiota in Inflammatory Bowel Disease Seth Bloom Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/etd Recommended Citation Bloom, Seth, "The Role of the Intestinal Microbiota in Inflammatory Bowel Disease" (2012). All Theses and Dissertations (ETDs). 555. https://openscholarship.wustl.edu/etd/555 This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Molecular Microbiology and Microbial Pathogenesis Dissertation Examination Committee: Thaddeus S. Stappenbeck, Chair Paul M. Allen Wm. Michael Dunne David B. Haslam David A. Hunstad Phillip I. Tarr Herbert W. “Skip” Virgin, IV The Role of the Intestinal Microbiota in Inflammatory Bowel Disease by Seth Michael Bloom A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May 2012 Saint Louis, Missouri Copyright By Seth Michael Bloom 2012 ABSTRACT OF THE DISSERTATION The Role of the Intestinal Microbiota in Inflammatory Bowel Disease by Seth Michael Bloom Doctor of Philosophy in Biology and Biomedical Sciences Molecular Microbiology and Microbial Pathogenesis Washington University in St. Louis, 2012 Professor Thaddeus S. Stappenbeck, Chairperson Inflammatory bowel disease (IBD) arises from complex interactions of genetic, environmental, and microbial factors.
    [Show full text]
  • Long-Read Metagenomics Retrieves Complete Single-Contig Bacterial Genomes from Canine Feces
    Cuscó et al. BMC Genomics (2021) 22:330 https://doi.org/10.1186/s12864-021-07607-0 RESEARCH Open Access Long-read metagenomics retrieves complete single-contig bacterial genomes from canine feces Anna Cuscó1*, Daniel Pérez2, Joaquim Viñes1,2, Norma Fàbregas1 and Olga Francino2 Abstract Background: Long-read sequencing in metagenomics facilitates the assembly of complete genomes out of complex microbial communities. These genomes include essential biologic information such as the ribosomal genes or the mobile genetic elements, which are usually missed with short-reads. We applied long-read metagenomics with Nanopore sequencing to retrieve high-quality metagenome-assembled genomes (HQ MAGs) from a dog fecal sample. Results: We used nanopore long-read metagenomics and frameshift aware correction on a canine fecal sample and retrieved eight single-contig HQ MAGs, which were > 90% complete with < 5% contamination, and contained most ribosomal genes and tRNAs. At the technical level, we demonstrated that a high-molecular-weight DNA extraction improved the metagenomics assembly contiguity, the recovery of the rRNA operons, and the retrieval of longer and circular contigs that are potential HQ MAGs. These HQ MAGs corresponded to Succinivibrio, Sutterella, Prevotellamassilia, Phascolarctobacterium, Catenibacterium, Blautia, and Enterococcus genera. Linking our results to previous gastrointestinal microbiome reports (metagenome or 16S rRNA-based), we found that some bacterial species on the gastrointestinal tract seem to be more canid-specific –Succinivibrio, Prevotellamassilia, Phascolarctobacterium, Blautia_A sp900541345–, whereas others are more broadly distributed among animal and human microbiomes –Sutterella, Catenibacterium, Enterococcus, and Blautia sp003287895. Sutterella HQ MAG is potentially the first reported genome assembly for Sutterella stercoricanis, as assigned by 16S rRNA gene similarity.
    [Show full text]
  • Gut Microbiota Analysis UC Davis MMPC - Microbiome & Host Response Core
    D4006- Gut Microbiota Analysis UC Davis MMPC - Microbiome & Host Response Core Contents 1 Methods: 1 1.1 Sequencing . .1 1.2 Data processing . .1 2 Summary of Findings: 2 2.1 Sequencing analysis . .2 2.2 Microbial diversity . .2 2.2.1 Alpha Diversity . .2 2.2.2 Beta Diversity . 10 2.3 Data analysis using taxa abundance data . 13 2.3.1 Stacked bar graphs of Taxa abundances at each level . 14 A Appendix 1 (Taxa Abundance Tables) 30 B Appendix 2 (Taxa removed from filtered datasets at each level) 37 References: 43 Core Contacts: Helen E. Raybould, Ph.D., Core Leader ([email protected]) Trina A. Knotts, Ph.D., Core Co-Leader ([email protected]) Michael L. Goodson, Ph.D., Core Scientist ([email protected]) Client(s): Kent Lloyd, DVM PhD ;MMRRC; UC Davis Project #: MBP-2079 MMRRC strain ID: MMRRC_043603 Animal Information: The strain was donated to the MMRRC by Jonathan Chernoff at Fox Chase Cancer Center. Fecal samples were obtained from animals housed under the care of Jonathan Chernoff at Fox Chase Cancer Center. 1 Methods: Brief Project Description: MMRRC strains are often contributed to the MMRRC to fulfill the resource sharing aspects of NIH grants. Since transporting mice to another facilty often causes a microbiota shift, having a record of the original fecal microbiota from the donor institution where the original phenotyping or testing was performed may prove helpful if a phenotype is lost after transfer. Several MMRRC mouse lines were selected for fecal microbiota profiling of the microbiota. Table 1: Animal-Strain Information X.SampleID TreatmentGroup Animal_ID Genotype Line Sex MMRRC.043603.M4 MMRRC.043603_Hom_M M4 Hom MMRRC.043603 M MMRRC.043603.M5 MMRRC.043603_Hom_M M5 Hom MMRRC.043603 M 1 1.1 Sequencing Frozen fecal or regional gut samples were shipped on dry ice to UC Davis MMPC and Host Microbe Systems Biology Core.
    [Show full text]
  • Confidential: for Review Only
    Supplementary material Gut Page 55 of 338 Gut 1 2 3 498 4 Supplementary Figure 1| Overview of the workflow for the multi-omics strategy 5 499 used in this study. Host phenome, serum and faecal metabolomes, and gut 6 500 microbiome of 235 ESRD patients and 81 healthy controls were characterised and 7 501 integrated into a multi-omics dataset. (A) Data types; (B) Differential filtering refers 8 9 502 to statistical significance computation based on differential abundance of features in 10 503 the patient and control groups; (C) Correlation and effect size analyses of multi-omics 11 504 dataset; (D) Predictive model building and clustering of metagenomics species with 12 Confidential: For Review Only 505 13 metabolites into co-abundance based networks; (E) Animal experiments testing the 14 506 effect of ESRD microbiota (left panel), ESRD-associated species (centre panel) and 15 507 probiotics (left panel). 16 508 17 18 509 Supplementary Figure 2| Differences in levels of serum metabolites between 19 510 ESRD patients and healthy controls. (A) Boxplot shows the serum metabolites that 20 511 differ significantly between ESRD patients and healthy controls. Top panel, ESRD 21 22 512 patient-enriched metabolites. Bottom panel, healthy control-enriched metabolites. The 23 513 uremic toxins that are enriched in ESRD patients are highlighted in red. Boxes 24 514 represent the interquartile range between the first and third quartiles and median 25 515 26 (internal line). Whiskers denote the lowest and highest values within 1.5 times the 27 516 range of the first and third quartiles, respectively; dots represent outliers beyond the 28 517 whiskers.
    [Show full text]
  • Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
    Published OnlineFirst September 26, 2016; DOI: 10.1158/1055-9965.EPI-16-0337 Research Article Cancer Epidemiology, Biomarkers Shifts in the Fecal Microbiota Associated with & Prevention Adenomatous Polyps Vanessa L. Hale1,2, Jun Chen3, Stephen Johnson3, Sean C. Harrington2, Tracy C. Yab4, Thomas C. Smyrk5, Heidi Nelson1, Lisa A. Boardman4, Brooke R. Druliner4, Theodore R. Levin6, Douglas K. Rex7, Dennis J. Ahnen8, Peter Lance9, David A. Ahlquist4, and Nicholas Chia1,2,10,11 Abstract Background: Adenomatous polyps are the most common production, as well as starch, sucrose, lipid, and phenylpropa- precursor to colorectal cancer, the second leading cause of cancer- noid metabolism. related death in the United States. We sought to learn more about Conclusions: These data hint that increased sugar, protein, and early events of carcinogenesis by investigating shifts in the gut lipid metabolism along with increased bile acid production could microbiota of patients with adenomas. promote a colonic environment that supports the growth of bile- Methods: We analyzed 16S rRNA gene sequences from the tolerant microbes such as Bilophilia and Desulfovibrio. In turn, these fecal microbiota of patients with adenomas (n ¼ 233) and microbes may produce genotoxic or inflammatory metabolites without (n ¼ 547). such as H2S and secondary bile acids, which could play a role in Results: Multiple taxa were significantly more abundant in catalyzing adenoma development and eventually colorectal patients with adenomas, including Bilophila, Desulfovibrio, cancer. proinflammatory bacteria in the genus Mogibacterium,and Impact: This study suggests a plausible biological mechanism multiple Bacteroidetes species. Patients without adenomas had to explain the links between shifts in the microbiota and colo- greater abundances of Veillonella, Firmicutes (Order Clostridia), rectal cancer.
    [Show full text]
  • Putative Mobilized Colistin Resistance Genes in the Human Gut Microbiome Bruno G
    Andrade et al. BMC Microbiology (2021) 21:220 https://doi.org/10.1186/s12866-021-02281-4 RESEARCH ARTICLE Open Access Putative mobilized colistin resistance genes in the human gut microbiome Bruno G. N. Andrade1, Tobias Goris2, Haithem Afli1, Felipe H. Coutinho3, Alberto M. R. Dávila4 and Rafael R. C. Cuadrat5,6* Abstract Background: The high incidence of bacterial genes that confer resistance to last-resort antibiotics, such as colistin, caused by mobilized colistin resistance (mcr) genes, poses an unprecedented threat to human health. Understanding the spread, evolution, and distribution of such genes among human populations will help in the development of strategies to diminish their occurrence. To tackle this problem, we investigated the distribution and prevalence of potential mcr genes in the human gut microbiome using a set of bioinformatics tools to screen the Unified Human Gastrointestinal Genome (UHGG) collection for the presence, synteny and phylogeny of putative mcr genes, and co-located antibiotic resistance genes. Results: A total of 2079 antibiotic resistance genes (ARGs) were classified as mcr genes in 2046 metagenome assembled genomes (MAGs), distributed across 1596 individuals from 41 countries, of which 215 were identified in plasmidial contigs. The genera that presented the largest number of mcr-like genes were Suterella and Parasuterella. Other potential pathogens carrying mcr genes belonged to the genus Vibrio, Escherichia and Campylobacter. Finally, we identified a total of 22,746 ARGs belonging to 21 different classes in the same 2046 MAGs, suggesting multi- resistance potential in the corresponding bacterial strains, increasing the concern of ARGs impact in the clinical settings. Conclusion: This study uncovers the diversity of mcr-like genes in the human gut microbiome.
    [Show full text]
  • Effects of Ammonia on Gut Microbiota and Growth Performance of Broiler Chickens
    animals Article Effects of Ammonia on Gut Microbiota and Growth Performance of Broiler Chickens Hongyu Han, Ying Zhou, Qingxiu Liu, Guangju Wang, Jinghai Feng and Minhong Zhang * State Key Laboratory of Animal Nutrition, Institute of Animal Sciences, Chinese Academy of Agricultural Sciences, Beijing 100193, China; [email protected] (H.H.); [email protected] (Y.Z.); [email protected] (Q.L.); [email protected] (G.W.); [email protected] (J.F.) * Correspondence: [email protected] Simple Summary: The composition and function of gut microbiota is crucial for the health of the host and closely related to animal growth performance. Factors that impact microbiota composition can also impact its productivity. Ammonia (NH3), one of the major contaminants in poultry houses, negatively affects poultry performance. However, the influence of ammonia on broiler intestinal microflora, and whether this influence is related to growth performance, has not been reported. Our results indicated that ammonia caused changes to cecal microflora of broilers, and these changes related to growth performance. Understanding the effects of ammonia on the intestinal microflora of broilers will be beneficial in making targeted decisions to minimize the negative effects of ammonia on broilers. Abstract: In order to investigate the influence of ammonia on broiler intestinal microflora and growth performance of broiler chickens, 288 21-day-old male Arbor Acres broilers with a similar weight were randomly divided into four groups with different NH3 levels: 0 ppm, 15 ppm, 25 ppm, and 35 ppm. The growth performance of each group was recorded and analyzed. Additionally, 16s rRNA Citation: Han, H.; Zhou, Y.; Liu, Q.; sequencing was performed on the cecal contents of the 0 ppm group and the 35 ppm group broilers.
    [Show full text]
  • Metabolome and Microbiota Analysis Reveals the Conducive Effect of Pediococcus Acidilactici BCC-1 and Xylan Oligosaccharides on Broiler Chickens
    fmicb-12-683905 May 23, 2021 Time: 14:38 # 1 ORIGINAL RESEARCH published: 28 May 2021 doi: 10.3389/fmicb.2021.683905 Metabolome and Microbiota Analysis Reveals the Conducive Effect of Pediococcus acidilactici BCC-1 and Xylan Oligosaccharides on Broiler Chickens Yuqin Wu1, Zhao Lei1, Youli Wang1, Dafei Yin1, Samuel E. Aggrey2, Yuming Guo1 and Jianmin Yuan1* 1 State Key Laboratory of Animal Nutrition, College of Animal Science and Technology, China Agricultural University, Beijing, China, 2 NutriGenomics Laboratory, Department of Poultry Science, University of Georgia, Athens, GA, United States Xylan oligosaccharides (XOS) can promote proliferation of Pediococcus acidilactic BCC-1, which benefits gut health and growth performance of broilers. The study aimed to investigate the effect of Pediococcus acidilactic BCC-1 (referred to BBC) and XOS on the gut metabolome and microbiota of broilers. The feed conversion ratio of BBC group, XOS group and combined XOS and BBC groups was lower Edited by: than the control group (P < 0.05). Combined XOS and BBC supplementation (MIX Michael Gänzle, group) elevated butyrate content of the cecum (P 0.05) and improved ileum University of Alberta, Canada < morphology by enhancing the ratio of the villus to crypt depth (P 0.05). The 16S Reviewed by: < Richard Ducatelle, rDNA results indicated that both XOS and BBC induced high abundance of butyric Ghent University, Belgium acid bacteria. XOS treatment elevated Clostridium XIVa and the BBC group enriched Shiyu Tao, Huazhong Agricultural University, Anaerotruncus and Faecalibacterium. In contrast, MIX group induced higher relative China abundance of Clostridiaceae XIVa, Clostridiaceae XIVb and Lachnospiraceae. Besides, *Correspondence: MIX group showed lower abundance of pathogenic bacteria such as Campylobacter.
    [Show full text]